Immunocore Holdings Plc (IMCR)

They are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX -- Immune mobilizing monoclonal TCRs Against X disease -- designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging their proprietary, flexible, off-the-shelf ImmTAX platform, they are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, they have dosed over 600 cancer patients with their ImmTAX product candidates, which they believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Their clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Their most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Industry
Biological Products (no Diagnostic Substances)

CEO	CFO
Bahija Jallal	Brian Di Donato

Bahija Jallal, Ph.D. has served as our Chief Executive Officer since January 2019. Previously, she served as President of MedImmune, LLC, at AstraZeneca plc’s global biologics research and development unit, and Executive Vice President of AstraZeneca plc and a member of its senior executive team, where she worked from 2008 to 2019. Prior to joining MedImmune, Dr. Jallal was vice president, drug assessment and development, at Chiron Corporation. Previously, she was part of the research team at Sugen, Inc. Dr. Jallal currently serves on the boards of directors of Anthem, Inc. and Guardant Health, Inc. She is also a member of the Board of Trustees of the Johns Hopkins University and the board of directors of the University of Maryland Health Sciences Research Park Corporation. Dr. Jallal is also a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine, and the immediate past president of the Association of Women in Science. Dr. Jallal received her Ph.D. in Physiology from Université de Paris VI, France and conducted her post-doctorate work in molecular biology and oncology at the Max Planck Institute for Biochemistry in Germany. We believe that Dr. Jallal’s extensive experience in the biotechnology industry, leading drug research and development efforts, her educational background and her knowledge of our company as our Chief Executive Officer, qualify her to serve on our board of directors.

Brian Di Donato has served as our Chief Financial Officer since April 2020. He joined us from Achillion Pharmaceuticals, Inc., where he was Senior Vice President and Chief Financial Officer from August 2018 to May 2020. Prior to joining Achillion, Mr. Di Donato was a private investor and a full-time student at Pennsylvania State University from May 2015 to May 2018. Previously, Mr. Di Donato held positions as Managing Director and Co-Portfolio Manager at Sorin Capital Management, where he worked from 2008 to 2014, and President and Chief Investment Officer at Capmark Investments, where he worked from 2002 to 2008. He also previously served as an Executive Director at Morgan Stanley and Vice President at UBS Securities LLC. Mr. Di Donato holds an M.B.A. from New York University’s Stern School of Business and B.S. degrees in biology from Penn State University and in mechanical engineering from Villanova University. Prior to business school, he was an aerospace engineering officer in the U.S. Navy.

Employees	Founded
291	2007

Address: 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom

Telephone: +44 1235 438600

Web page: http://www.immunocore.com

Expected Date	2/5/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the IMCR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Goldman Sachs

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Goldman Sachs/ JP Morgan/ Jefferies
CO-Managers
-